Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16171993rdf:typepubmed:Citationlld:pubmed
pubmed-article:16171993lifeskim:mentionsumls-concept:C0085134lld:lifeskim
pubmed-article:16171993lifeskim:mentionsumls-concept:C0521390lld:lifeskim
pubmed-article:16171993lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:16171993lifeskim:mentionsumls-concept:C0034830lld:lifeskim
pubmed-article:16171993lifeskim:mentionsumls-concept:C0031960lld:lifeskim
pubmed-article:16171993lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:16171993lifeskim:mentionsumls-concept:C0728938lld:lifeskim
pubmed-article:16171993lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:16171993lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:16171993pubmed:issue22lld:pubmed
pubmed-article:16171993pubmed:dateCreated2005-10-5lld:pubmed
pubmed-article:16171993pubmed:abstractText3,5-Bicyclic aryl piperidines are a new class of high-affinity alpha4beta2 nicotinic receptor agents. We have sought nicotinic receptor partial agonists of the alpha4beta2 nicotinic acetylcholine receptor for smoking cessation, and a number of compounds fulfill potency, selectivity, and efficacy requirements in vitro. In vivo, selected agents demonstrate potent partial agonist efficacy on the mesolimbic dopamine system, a key measure of therapeutic potential for smoking cessation.lld:pubmed
pubmed-article:16171993pubmed:languageenglld:pubmed
pubmed-article:16171993pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16171993pubmed:citationSubsetIMlld:pubmed
pubmed-article:16171993pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16171993pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16171993pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16171993pubmed:statusMEDLINElld:pubmed
pubmed-article:16171993pubmed:monthNovlld:pubmed
pubmed-article:16171993pubmed:issn0960-894Xlld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:SchulzDavid...lld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:BashoreCrysta...lld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:CoeJotham WJWlld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:MansbachRober...lld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:BiancoKrista...lld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:BrooksPaige...lld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:VetelinoMicha...lld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:WirtzMichael...lld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:O'NeillBrian...lld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:RollemaHansHlld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:ArnoldEric...lld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:SandsSteven...lld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:DavisThomas...lld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:LebelLorraine...lld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:FoxCarol BCBlld:pubmed
pubmed-article:16171993pubmed:authorpubmed-author:TingleyF...lld:pubmed
pubmed-article:16171993pubmed:issnTypePrintlld:pubmed
pubmed-article:16171993pubmed:day15lld:pubmed
pubmed-article:16171993pubmed:volume15lld:pubmed
pubmed-article:16171993pubmed:ownerNLMlld:pubmed
pubmed-article:16171993pubmed:authorsCompleteYlld:pubmed
pubmed-article:16171993pubmed:pagination4889-97lld:pubmed
pubmed-article:16171993pubmed:meshHeadingpubmed-meshheading:16171993...lld:pubmed
pubmed-article:16171993pubmed:meshHeadingpubmed-meshheading:16171993...lld:pubmed
pubmed-article:16171993pubmed:meshHeadingpubmed-meshheading:16171993...lld:pubmed
pubmed-article:16171993pubmed:meshHeadingpubmed-meshheading:16171993...lld:pubmed
pubmed-article:16171993pubmed:meshHeadingpubmed-meshheading:16171993...lld:pubmed
pubmed-article:16171993pubmed:meshHeadingpubmed-meshheading:16171993...lld:pubmed
pubmed-article:16171993pubmed:meshHeadingpubmed-meshheading:16171993...lld:pubmed
pubmed-article:16171993pubmed:meshHeadingpubmed-meshheading:16171993...lld:pubmed
pubmed-article:16171993pubmed:year2005lld:pubmed
pubmed-article:16171993pubmed:articleTitle3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation.lld:pubmed
pubmed-article:16171993pubmed:affiliationPfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA. jwcoe@pfizer.comlld:pubmed
pubmed-article:16171993pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:16171993lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16171993lld:pubmed